Last reviewed · How we verify
Poor metabolisers — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Poor metabolisers (Poor metabolisers) — Radboud University Medical Center. Poor metabolisers is not a drug but a pharmacogenetic classification describing individuals with reduced capacity to metabolize certain medications due to genetic variations in drug-metabolizing enzymes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Poor metabolisers TARGET | Poor metabolisers | Radboud University Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Poor metabolisers CI watch — RSS
- Poor metabolisers CI watch — Atom
- Poor metabolisers CI watch — JSON
- Poor metabolisers alone — RSS
Cite this brief
Drug Landscape (2026). Poor metabolisers — Competitive Intelligence Brief. https://druglandscape.com/ci/poor-metabolisers. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab